CHCWM – Cancer & Hematology Centers of West Michigan

XMT-1592 (Mersana)

A Phase 1b, First-in-Human, Dose Escalation and Expansion Study of XMT-1592 In Patients with Solid Tumors Likely to Express NaPi2b